NICE (UK);Trifluridine–tipiracil (Lonsurf) is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.
The European Commission (EC) has granted marketing authorization for Lonsurf (trifluridine/tipiracil), formerly known as TAS-102, from Taiho Pharmaceutical Co, in...
Taiho Pharmaceutical Co has announced results from its Phase III TERRA study on its oral combination anticancer drug TAS-102 or...
The FDA has approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) from Taiho for patients with an...
Taiho Pharmaceutical Co., Ltd. and Servier Laboratories announced that they have entered into an exclusive license agreement on June 12,...
Servier and Taiho Oncology announced the release of data from SUNLIGHT, a pivotal Phase III global trial evaluating the combination of Lonsurf (trifluridine/tipiracil) and Avastin (bevacizumab) in adults with refractory metastatic colorectal cancer (mCRC), demonstrating that the trial met its primary endpoint of overall survival (OS)
Servier announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...